Posted On: 07/14/2014 4:11:18 PM
Post# of 30066
Whew, what a day!
And tomorrow is the big day.
I like what GC says in his last blog about the poster tomorrow. I brought it over for your convenience. Look at the last sentence.
I believe the answer to this rhetorical question is, uh, YES!
Patients prevails,
GO AMBS
And tomorrow is the big day.
I like what GC says in his last blog about the poster tomorrow. I brought it over for your convenience. Look at the last sentence.
Quote:
Longitudinal Clinical Performance – Data will be presented from a follow-up patient record study of the Version 2 Clinical Performance Data mentioned above. We believe this data is the most scientifically relevant as it will add significant validity to the original Version 2 data by giving us an assessment of the change in physician’s diagnosis over time as compared to the LymPro score. Of highest potential value is whether LymPro was able to identify pre-symptomatic patients who would eventually progress to symptomatic AD (false-negatives). - See more at: www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/aaic-2014-understanding-data-presented-lympro-test-version-2/#sthash.RaQBFNEg.dpuf
I believe the answer to this rhetorical question is, uh, YES!
Patients prevails,
GO AMBS
(0)
(0)
